Holen Sie sich die Stockscreener-App
39.75
0.03%
-0.010
Schlusskurs vom Vortag:
$39.76
Offen:
$39.76
24-Stunden-Volumen:
2.22M
Relative Volume:
0.87
Marktkapitalisierung:
$6.15B
Einnahmen:
$15.06M
Nettoeinkommen (Verlust:
$-250.69M
KGV:
-22.40
EPS:
-1.7748
Netto-Cashflow:
$-209.28M
1W Leistung:
-0.03%
1M Leistung:
+0.40%
6M Leistung:
+54.55%
1J Leistung:
+215.48%
1-Tages-Spanne:
$39.66
$39.80
1-Wochen-Bereich:
$39.64
$39.83
52-Wochen-Spanne:
$12.30
$40.26
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Firmenname
Centessa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
44 7391 789784
Adresse
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
39.75 | 6.15B | 15.06M | -250.69M | -209.28M | -1.7748 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | Truist | Buy → Hold |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-12-10 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-29 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-05-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-07-18 | Eingeleitet | Oppenheimer | Outperform |
| 2023-11-15 | Hochstufung | Jefferies | Hold → Buy |
| 2023-10-26 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | Eingeleitet | Evercore ISI | Outperform |
| 2023-06-12 | Eingeleitet | Guggenheim | Buy |
| 2023-03-17 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-12 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Centessa Pharmaceuticals Plc Adr Aktie (CNTA) Neueste Nachrichten
Centessa (NASDAQ: CNTA) investors approve Eli Lilly acquisition scheme - Stock Titan
TD Asset Management Inc Decreases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Gold gains over 1%; FactSet Research raises FY2026 outlook - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—RAMP, NEE, CNTA, and HCBN - GlobeNewswire Inc.
Eli Lilly, Centessa Pharmaceuticals receive US green light - MLex
HSR waiting period lapses for Centessa (CNTA) sale to Eli Lilly under UK scheme - Stock Titan
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plcCNTA - ChartMill
Centessa (NASDAQ: CNTA) to be acquired by Lilly for $38 plus up to $9 CVR - Stock Titan
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge? - Yahoo Finance
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighStill a Buy? - MarketBeat
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised - TradingView
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Centessa (NASDAQ: CNTA) schedules 2026 AGM and advisory pay vote - Stock Titan
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG - MarketBeat
Should You Buy, Sell or Hold Lilly Stock Before Q1 Earnings? - TradingView
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35 - marketscreener.com
Lilly to buy Centessa (NASDAQ: CNTA) for $38/ share plus $9 CVR - Stock Titan
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Sahm
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Finanzdaten der Centessa Pharmaceuticals Plc Adr-Aktie (CNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Centessa Pharmaceuticals Plc Adr-Aktie (CNTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Anderson Karen M. | Chief People Officer |
Mar 26 '26 |
Sale |
30.12 |
41,076 |
1,237,382 |
62,085 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Option Exercise |
3.85 |
23,998 |
92,392 |
89,923 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Sale |
30.00 |
23,998 |
719,940 |
65,925 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):